CIK 0000899923 · Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 870494517
- Phone
- 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- 8-K Event Regulation FD disclosure
- 4 Shares withheld for taxes Chief Financial Officer gave up 12,336 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Commercial Officer gave up 8,366 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Operating Officer gave up 12,111 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Technology Officer gave up 1,710 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 308 shares (to pay taxes)
- 8-K Event Executive or director change · Regulation FD disclosure
- 4 Shares withheld for taxes Chief Financial Officer gave up 4,517 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Commercial Officer gave up 3,523 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Operating Officer gave up 4,402 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Technology Officer gave up 858 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 133 shares (to pay taxes)
- 4 Grant or award Chief Accounting Officer acquired 10,000 shares (grant or award)
- 4 Grant or award SVP, Chief of Staff acquired 10,000 shares (grant or award)
- 4 Shares withheld for taxes Chief Commercial Officer gave up 1,076 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Accounting Officer gave up 218 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 74,235 shares (to pay taxes)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations · Unregistered share sale · Other events
- 8-K Event Material agreement · New debt or obligation · Other events
Page 16 of 104 · 2,077 filings